Radionuclide imaging of drug delivery for patient selection in targeted therapy

Expert Opinion on Drug Delivery

Volumn 11, Issue 2, 2014, Pages 175-185

  Heskamp, Sandra ^a   Van Laarhoven, Hanneke Wm ^a,b   Van Der Graaf, Winette Ta ^a   Oyen, Wim Jg ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antibody; Biomarker; Cancer; Drug delivery; Molecular imaging; PET; SPECT; Tyrosine kinase inhibitor

Indexed keywords

BIOLOGICAL MARKER; PROTEIN TYROSINE KINASE INHIBITOR; RADIOISOTOPE; ANTINEOPLASTIC AGENT;

ANTIGEN EXPRESSION; BIOLUMINESCENCE; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; GENE EXPRESSION; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICS; PATIENT SAFETY; PATIENT SELECTION; PROTEIN LOCALIZATION; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT RESPONSE; TUMOR BIOPSY; ULTRASOUND; ANIMAL; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR IMAGING; NEOPLASMS; PATIENT SELECTION;

EID: 84892729869     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.870552     Document Type: Review

References (66)

1. Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: portals of discovery. Clin Cancer Res 2012;18:23-32
2. Collier R. Rapidly rising clinical trial costs worry researchers. CMAJ 2009;180:277-8
3. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21
4. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7
5. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration Study. J Clin Oncol 2011;29:4541-7
6. Malempati S, Weigel B, Ingle AM, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012;30:256-62
7. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35
8. Kaufman PA, Ferrero JM, Bourgeois H, et al. Abstract S1-4: a Randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormonereceptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res 2010;70:S1-4
9. Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011;29:4574-80
10. Watkins DJ, Tabernero J, Schmoll H, et al. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. J Clin Oncol 2011;29(Suppl):abstract 3501
11. Bang YJ, Van CE, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
12. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
13. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
14. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95
15. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
16. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78
17. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312
18. Katsios C, Ziogas DE, Roukos DH. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. Expert Rev Gastroenterol Hepatol 2010;4:525-9
19. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
20. Tolmachev V, Malmberg J, Hofstrom C, et al. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. J Nucl Med 2012;53:90-7
21. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586-92
22. Scheer MG, Stollman TH, Boerman OC, et al. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression. Eur J Cancer 2008;44:1835-40
23. Van der Veldt AA, Lubberink M, Bahce I, et al. Rapid decrease in delivery of chemotherapy to tumors after Anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012;21:82-91
24. Memon AA, Weber B, Winterdahl M, et al. PET imaging of patients with nonsmall cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer 2011;105:1850-5
25. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13
26. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-63
27. Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50:123-31
28. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, et al. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 2011;17:7693-703
29. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766-74
30. Peterson LM, Mankoff DA, Lawton T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 2008;49:367-74
31. Mortimer JE, Dehdashti F, Siegel BA, et al. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996;2:933-9
32. McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-31
33. Toonen EJ, FleurenWW, Nassander U, et al. Prednisolone-induced changes in geneexpression profiles in healthy volunteers. Pharmacogenomics 2011;12:985-98
34. Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113:301-6
35. Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552-6
36. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27
37. Hnatowich DJ. Label stability in serum of four radionuclides on DTPA-coupled antibodies-an evaluation. Int J Rad Appl Instrum B 1986;13:353-8
38. Lub-de Hooge MN, Kosterink JG, Perik PJ, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004;143:99-106
39. Stollman TH, Scheer MG, Franssen GM, et al. Tumor accumulation of radiolabeled bevacizumab due to targeting of cell-and matrix-associated VEGF-A isoforms. Cancer Biother Radiopharm 2009;24:195-200
40. Arjaans M, Oude Munnink TH, Oosting SF, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013;73:3347-55
41. Heskamp S, Boerman OC, Molkenboer-Kuenen JD, et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer 2013;133:307-14
42. Pastuskovas CV, Mundo EE, Williams SP, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 2012;11(3):752-62
43. Desar IM, Stillebroer AB, Oosterwijk E, et al. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med 2010;51:1707-15
44. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51
45. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med 2010;51:1565-72
46. Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, et al. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. Int J Cancer 2011;129:870-8
47. Heskamp S, Boerman OC, Molkenboer-Kuenen JD, et al. Bevacizumab reduces tumor targeting of anti-epidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer 2013;133(2):307-14
48. Dijkers EC, Kosterink JG, Rademaker AP, et al. Development and characterization of clinical-grade 89Zrtrastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009;50:974-81
49. Fischman AJ. When magic bullets ricochet. J Nucl Med 1990;31:32-3
50. Oude Munnink TH, de Vries EG, Vedelaar SR, et al. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts. Mol Pharm 2012;9:2995-3002
51. Rudnick SI, Lou J, Shaller CC, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011;71:2250-9
52. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004;15:5268-82
53. Gilboa L, Ben-Levy R, Yarden Y, Henis YI. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. J Biol Chem 1995;270:7061-7
54. Tolmachev V, Wallberg H, Sandstrom M, et al. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging 2011;38:531-9
55. Bruno R,Washington CB, Lu JF, et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005;56:361-9
56. Tolmachev V, Rosik D, Wallberg H, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37:613-22
57. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97-104
58. Yeh HH, Ogawa K, Balatoni J, et al. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinaseexpressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci USA 2011;108:1603-8
59. Weber B, Winterdahl M, Memon A, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011;6:1287-9
60. Meng X, Loo BWJr, Ma L, et al. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med 2011;52:1573-9
61. McLarty K, Cornelissen B, Scollard DA, et al. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 2009;36:81-93
62. Achmad A, Hanaoka H, Yoshioka H, et al. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Cancer Sci 2012;103:600-5
63. Aurisicchio L, Marra E, Roscilli G, et al. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget 2012;3:744-58
64. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol 2013;31:1089-96
65. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
66. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54